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1. Introduction
About two decades ago recombinant human immunodeficiency virus type 1 (HIV-1) was
proposed as a blueprint for the development of lentiviral vectors (LVs) (Naldini, Blomer et
al. 1996). Lentiviral vectors exhibit several characteristics that make them favorable tools for
gene therapy, including sustained gene delivery through vector integration, transduction of
both dividing and non-dividing cells, applicability to different target cell types, absence of
expression of viral proteins after transduction, delivery of complex genetic elements, low
genotoxicity and the relative ease of vector manipulation and production (Cattoglio, Facchi‐
ni et al. 2007; Bauer, Dao et al. 2008). This is reflected in the numerous applications such as:
transgene (tg) overexpression (Lopez-Ornelas, Mejia-Castillo et al. 2011), persistent gene si‐
lencing (Wang, Hu et al. 2012), immunization (Breckpot, Emeagi et al. 2008), generation of
transgenic animals (Baup, Fraga et al. 2010), in vivo imaging (Roet, Eggers et al. 2012), induc‐
tion of pluripotent cells, stem cell modification (Sanchez-Danes, Consiglio et al. 2012), line‐
age tracking and site-directed gene editing (Lombardo, Genovese et al. 2007) as well as
many applications targeting cancer cells (Petrigliano, Virk et al. 2009).
Recombinant LVs can be derived from primate as well as non-primate lentiviruses such as
HIV-1 and simian immunodeficiency virus (SIV) next to the equine infectious anemia virus,
caprine arthritis-encephalitis virus, maedi-visna virus, feline immunodeficiency virus (FIV)
and bovine immunodeficiency virus respectively (Escors and Breckpot 2010). They are all
members of the Retroviridae family with ‘retro’ referring to their capacity to retro-transcribe
their diploid single stranded (ss) RNA genome into a double stranded (ds) DNA copy that is
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integrated in the genome of the infected host cell (Figure 1A). Since LVs are most often de‐
rived from HIV-1, the generation of recombinant LVs has been accompanied by several safety
concerns such as the generation of replication-competent lentiviruses (RCLs). Another poten‐
tial biosafety concern is the induction of insertional mutagenesis, a major genotoxic problem
that emerged in gene therapy clinical trials using their γ-retroviral counterparts (Manilla, Re‐
bello et al. 2005). Generally, LVs are produced by transiently transfecting HEK 293 or 293T
cells with plasmids encoding structural and functional sequences, imperative for proper LV
particle generation. Over the last decades, vector development has largely focused on the de‐
sign of these plasmids. Firstly, only critical viral structural and functional sequences are pro‐
vided  and  secondly,  these  sequences  are  divided  over  a  certain  number  of  individual
plasmids either in cis (encoded by the LV) or trans (packaged as a protein within the LV parti‐
cle), with a minimal overlap between viral sequences. This led to a LV production procedure
where at least three different plasmids are used: (1) a packaging plasmid which provides all
viral structural and enzymatic sequences (encoded by gag and pol) in trans to generate a func‐
tional particle, (2) a transfer plasmid providing the expression cassette in cis, cloned into the
non-coding remains of the original lentiviral genome (Figure 1B, adapted from (Delenda
2004)) including a packaging signal and the two long terminal repeats (LTRs) of which the
promoter activity has been deleted from the 3’ LTR and (3) an envelope plasmid encoding an
envelope glycoprotein (gp) consisting of a transmembranary domain (TM) and a receptor-
binding domain (SU) that determines the LVs’ tropism (Figure 1A).
Figure 1. Schematic representation of an HIV-1 particle (A) and its genome (B). The diploid ssRNA genome of
HIV-1 is stabilized by structural nucleocapsid proteins and together with the enzymatic proteins reverse transcriptase,
protease and integrase packaged in a nucleocapsid structure, which in turn is enclosed by capsid proteins. This nucleo‐
capsid is surrounded by a matrix protein layer and a producer cell derived phospholipid bilayer in which the envelope
proteins consisting of an SU and TM part, are embedded (A). All proviral genes (gag, pol, pro, vif, vpr, vpu, ref, tat, env
en nef) are flanked by two identical LTRs that consist of three regions: U3, R and U5. Within the U3 region, all proviral
transcriptional control elements are situated such as the promoter and several enhancer sequences. Ψ represents the
packaging signal. At the 3’ end of the pol gene the central polypurine tract (red) and central termination sequence
(green) are located. Both ensure the formation of a triple stranded DNA flap, crucial for nuclear entry of the pre-inte‐
gration complex in non-dividing cells (B).
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Besides  this  division  over  different  plasmids,  other  important  construct  optimization
steps have been implemented.  While  in  the first  generation LV packaging plasmids the
entire gag  and pol  genes were encoded together with all  accessory regulatory and viru‐
lence genes, the second generation was multiply attenuated by removal of the four viru‐
lence  genes,  but  not  the  regulatory genes  tat  and rev  (Zufferey,  Nagy et  al.  1997).  In  the
third generation,  the rev  gene is  expressed from a separate  plasmid and the tat  gene is
removed by insertion of a strong constitutive promoter replacing the U3 region in the 5’
LTR of the transfer plasmid (Dull,  Zufferey et al.  1998).  A major improvement was ach‐
ieved with the development of  SIN or  self-inactivating LVs where a  deletion in the U3
region of the 3’ LTR of the transfer plasmid abolished the production of full-length vec‐
tor  RNA  in  transduced  cells.  This  not  only  minimizes  the  risk  for  RCLs,  but  also  re‐
duces  the  chance  that  the  viral  LTR  enhancers  interfere  with  the  expression  cassette,
which  minimizes  aberrant  expression  of  adjacent  cellular  coding  regions.  Subsequently
these  and many other  optimization  steps  paved the  way towards  a  more  effective  and
safer version of the lentiviral gene delivery vehicle (Romano, Claudio et al. 2003).
In  addition  to  packaging  and transfer  plasmid  optimization,  also  the  envelope  plasmid
was modified by replacing the natural  HIV-1 envelope gp with an alternative  gp gene,
most  often  the  gp  of  vesicular  stomatitis  virus  (VSV.G).  This  concept  is  called  pseudo‐
typing and VSV.G endowed the LV particle with an increased stability and broad cellu‐
lar  tropism  (to  most  if  not  all  mammalian  cells).  However,  it  became  clear  that  for
numerous in vivo applications, a broad tropism may not be desirable. First, the tg that is
encoded could be toxic to many cell types, e.g. pro-apoptotic or suicide genes, so a strin‐
gent control over the induction of tg expression in time and/or place is a necessity (Uch,
Gerolami et al.  2003; Seo, Kim et al.  2009).  A second point of concern is the risk for in‐
sertional mutagenesis; the more cells get infected, the higher this risk becomes. Although
it has been demonstrated that LVs intrinsically exhibit low genotoxicity, clonal expansion
and dominance of transduced hematopoietic progenitors have been reported in a clinical
trial  in  which  hematopoietic  stem  cells  were  genetically  modified  with  a  LV  that  ex‐
pressed the β-globin gene for treatment of β-thalassemia (Fehse and Roeder 2008; Cavaz‐
zana-Calvo,  Payen et  al.  2010).  Thirdly,  while  a  broad tropism LV is  favorable  in  anti-
tumor immunotherapy to efficiently transduce antigen-presenting cells (APCs) which can
induce  an antigen specific  immune response  (Palmowski,  Lopes  et  al.  2004),  this  is  not
desirable when a genetic  disorder has to be restored as in this  case the tg may not  be‐
come an immunological target (Annoni, Battaglia et al.  2007). Finally, during production
of pantropic viruses encoding oncogenes, narrow tropism vectors would be more valua‐
ble  due  to  biosafety  level  handling  requirements  and  safety  issues  (Barrilleaux  and
Knoepfler  2011).  Therefore,  in  view of  safety as  well  as  applicability  aspects,  four main
targeting  strategies  can  be  brought  forward:  targeted gene  expression or  transcriptional
targeting,  targeted gene translation or  microRNA based (de)targeting,  targeted infection
or transductional targeting, and targeted integration of the proviral DNA.
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2. Transcriptional targeting
Most often a strong constitutive promoter with or without enhancer sequences is used to
drive the LV encoded tg. These include the cytomegalovirus (CMV), spleen focus forming
virus (SFFV), human polypeptide chain elongation factor-1alpha (EF-1alpha), phosphogly‐
cerate kinase (PGK) and ubiquitin C promoters (Kim, Kim et al. 2007; Gilham, Lie et al. 2010;
Li, Husic et al. 2010). Although these promoters generally induce strong and ubiquitous ex‐
pression of the tg, they present some disadvantages. A first drawback is that they are more
prone to promoter inactivation than cell-specific promoters. In addition, they are more po‐
tent in terms of activating the host-cell defense machinery and increasing the long-distance
effects of insertional mutagenesis caused by their enhancer sequences (Liu, Wang et al. 2004;
Stein, Ott et al. 2010; Singhal, Deng et al. 2011). These downsides resulted in the develop‐
ment of various strategies to allow cell-specific tg expression by incorporating cell type spe‐
cific regulatory elements and/or promoter(s) in the expression cassette of the LV. Because of
the availability of a large number of endogenous cellular promoters, targeted expression can
be achieved to potentially any cell type or tissue. In addition, its advantage over unselective
expression has been demonstrated in numerous studies (Di Nunzio, Maruggi et al. 2008;
Kerns, Ryu et al. 2010; Cao, Sodhi et al. 2011). This is exemplified by a study where LV en‐
coding iduronidase under the control of the hepatocyte specific albumin gene promoter was
injected intravenously to treat mucopolysaccharidosis type I. While the same LV with a
CMV promoter resulted in the induction of an immune response that diminished the tg ex‐
pression over time, the albumin gene promoter enabled stable and prolonged tg expression
with a partial correction of the pathology (Di Domenico, Di Napoli et al. 2006). In addition
to hepatocyte specific targeting, an ever-growing list of cell-type specific promoters has been
used for the specific expression in tissues such as the erythroid lineage, endothelial cells,
myocardial cells, retinal cells, B cells, epidermal, hematopoietic stem cells, etcetera (Hanawa,
Persons et al. 2002; De Palma, Venneri et al. 2003; Semple-Rowland, Eccles et al. 2007; Di
Nunzio, Maruggi et al. 2008; Leuci, Gammaitoni et al. 2009; Kerns, Ryu et al. 2010; Semple-
Rowland, Coggin et al. 2010; Cao, Sodhi et al. 2011; Lee, Fan et al. 2011; Friedrich, Nopora et
al. 2012).
Besides the advantage of increased and prolonged expression levels when expressed in the
target cell of choice, targeted expression can also be a necessity when the tg causes undesira‐
ble damage in non-target cells. For the treatment of Mpl-deficient aplastic anemia, for exam‐
ple, targeted transfer to hematopoietic stem cells is inevitable since ectopic Mpl expression
causes lethal adverse reactions (Heckl, Wicke et al. 2011). The same holds true for toxin, pro-
apoptotic or suicide gene encoding LVs used in anti-tumor therapy (Zheng, Chen et al. 2003;
Hsieh, Chen et al. 2011). LVs are excellent candidates to modulate the tumor and its environ‐
ment since they transduce both dividing cells such as most cancer cells but also non- or very
slowly dividing cells such as cancer stem cells. Furthermore LVs are able to integrate in the
genome of transduced cells, potentially generating clonal populations of genetically modi‐
fied cancer cells, which may then spread throughout the tumor mass (Steffens, Tebbets et al.
2004). Vector targeting can be attempted by local vector delivery, although this raises practi‐
cal concerns for non-solid and metastatic tumor cells. Consequently, systemic delivery of a
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targeted LVs and subsequent exclusive tg expression in cancer cells is the ultimate goal.
Metastatic prostate cancer, for example, has been transcriptionally targeted in various ways
(1) using a prostate-specific antigen (PSA) promoter to drive the expression of diphtheria
toxin A, (2) using the prostate-stem cell antigen (PSCA) promoter to drive the expression of
the Herpes Simplex Virus thymidine kinase (HSV-TK) suicide gene, or (3) combining the
prostate-specific promoter ARR2PB and a short DNA sequence in the 5’-untranslated region
that is recognized by the translation initiation factor eIF4E, often overexpressed in malignant
cells, to drive the expression of the HSV-TK suicide gene (Yu, Chen et al. 2001; Zheng, Chen
et al. 2003; Yu, Scott et al. 2006; Kimura, Koya et al. 2007; Petrigliano, Virk et al. 2009). Addi‐
tionally, the tumor vasculature has been transcriptionally targeted using the endothelial spe‐
cific Tie2 promoter to drive the conditionally toxic nitroreductase and subsequently
diminish tumor growth (De Palma, Venneri et al. 2003). Another cancer cell type specific tar‐
geting strategy to limit tg expression to hepatocarcinoma was applied by Uch et al. They
constructed a LV expressing HSV-TK under the control of the rat alpha-fetoprotein promot‐
er elements (Uch, Gerolami et al. 2003). Besides cancer cell type specific strategies, also more
generalized cancer targeting strategies have been developed. For example, as the human te‐
lomerase reverse transcriptase (hTERT) is expressed in most malignant tumors, its promoter
has been used to drive the expression of the cytosine deaminase gene together with a green
fluorescent protein (GFP) reporter gene. It was demonstrated that hTERT-positive tumors
could be visualized after intratumoral injection of the LV in tumor-bearing nude mice and,
more importantly, that significant tumor growth suppression was observed after delivery of
the pro-drug 5-fluorocytosine (Yu, Li et al. 2011). Besides avoidance of toxic tg expression in
a non-tumor cell, tumor specific gene therapy is also interesting for targeted imaging. For
example, the use of the chimeric promoter EIIAPA containing the alpha-fetoprotein promot‐
er and hepatitis B virus enhancer II was used to control the downstream expression of luci‐
ferase genes to subsequently assay the selective transcriptional activity by bioluminescence
imaging (Hsieh, Chen et al. 2011).
As LVs efficiently infect non-dividing cells, they provide suitable platforms for tg delivery
to multiple mammalian neuronal cell types. It has been shown that stereotactic injection of
LVs in the brain parenchyma leads to transduction of the striatum, hippocampus and thala‐
mus (Watson, Kobinger et al. 2002). Moreover, transcriptional targeting has proven to be a
reliable technique to unravel the complexity of the nervous system by neuron and brain spe‐
cific assessment of the effects of therapeutic proteins and RNA interference, or to investigate
neuronal gene expression (Hioki, Kameda et al. 2007; Gascon, Paez-Gomez et al. 2008; Kuro‐
da, Kutner et al. 2008; Peviani, Kurosaki et al. 2012). Regulatory sequences of rat neuron spe‐
cific enolase, human glial fibrillary acidic protein and myelin basic protein have already
been exploited to obtain LV-mediated selective gene targeting of neurons, astrocytes and oli‐
godendrocytes, respectively (Jakobsson, Ericson et al. 2003; McIver, Lee et al. 2005). This has
led to applications like subregional tg expression in the hippocampus using the hybrid
hEF1alfa/HTLV promoter or neuron specific synapsin I promoter or targeting the central se‐
rotonergic neurons using a two-step transcriptional amplification strategy co-expressing the
tryptophan hydroxylase-2 gene promoter with the chimeric enhancer GAL4/p65 (Kuroda,
Kutner et al. 2008; Benzekhroufa, Liu et al. 2009). Next to the central nervous system, Bend‐
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otti et al. recently focused on selective tg expression in mouse spinal cord motor neurons us‐
ing motor neuron specific regulatory sequences derived from the promoter of the homeobox
gene Hb9 (Benzekhroufa, Liu et al. 2009; Peviani, Kurosaki et al. 2012). However, neuron
specific gene expression is not always very efficient and therefore several groups have at‐
tempted to improve the endogenous promoters using extra enhancers or artificial transcrip‐
tional activators such as the bidirectional promoter. For the latter, Liu et al. based their
bidirectional promoter on the transcriptional activity of the human synapsin-1 promoter and
the compact glial fibrillary acidic protein (GfaABC1D) promoter. In the opposite orientation,
a minimal core promoter of 65 basepairs (bp) derived from the CMV promoter was joined
upstream of both promoters, which were flanked with two gene expression cassettes. The 5’
cassette transcribed the artificial transcriptional activator while the downstream cassette
drove the expression of the gene of interest (Liu, Paton et al. 2008).
To fulfill the high expectations of gene therapy, both efficient delivery and sustained ex‐
pression of  the  therapeutic  gene are  essential  requirements.  However,  one  of  the  major
barriers  to  stable  gene  transfer  by  LVs  is  the  development  of  innate  and  adaptive  im‐
mune responses to the delivery vector and the transferred therapeutic tg. It became clear
that  in  vivo  administered  broad  tropism LVs  efficiently  transduce  APCs  and  that  these
play a major role in the induction of tg specific immune responses (Annoni, Battaglia et
al.  2007;  Vandendriessche,  Thorrez  et  al.  2007).  Consequently  transcriptional  targeting
can  be  applied  to  avoid  tg  expression  in  APCs.  Brown et  al.  demonstrated  stable  GFP
production by modified cells in vivo when tg expression was prevented in APCs (Brown,
Venneri et al. 2006). Another study combined the hepatocyte specific enhanced transthyr‐
etin  promoter  with  an  APC-detargeting  microRNA strategy,  and  showed the  induction
of GFP-specific regulatory T cells and the promotion of immunological tolerance (Anno‐
ni, Brown et al. 2009 ). Moreover, Matrai et al. demonstrated that hepatocyte-targeted ex‐
pression by an integrase-defective LV (IDLV) induced tolerance to coagulation factor IX
with  prevention  of  the  induction  of  neutralizing  antibodies  in  mice  (Matrai,  Cantore  et
al. 2011). In contrast to gene therapy, immunotherapy pursuits the induction of a tg-spe‐
cific  immune  response  where  APC-specific  transduction  is  imperative.  Therefore,  LVs
that drive tg expression via an APC-specific promoter have been developed. For instance
Cui et al. used the HLA-DR promoter to target human MHC class II+  cells like dendritic
cells (DCs, CD83+) and macrophages (CD14+).  They demonstrated the induction of an al‐
logeneic T cell response in vitro (Cui, Golob et al. 2002). The dectin-2 promoter was used
to target the expression of the human melanoma antigen NY-ESO-1 to murine APCs. Af‐
ter  intravenous injection of  the targeted LVs,  selective tg expression in dectin-2+  splenic
myeloid and plasmacytoid DCs as well as in F4/80+  macrophages was reported. Further‐
more CD11c+  draining lymph node residing DCs were targeted after subcutaneous injec‐
tion which resulted in strong NY-ESO-1 specific CD8+  and CD4+  T cell responses (Lopes,
Dewannieux  et  al.  2008).  On the  other  hand,  DC-induced tg  specific  tolerance  has  also
been achieved after the use of a DC-specific promoter. When LVs carrying a CD11c pro‐
moter were used to make DC-specific transgenic mice by injecting the purified virus into
the  perivitelline  space  of  single-cell  embryos,  the  tg  became  an  autologous  antigen  to
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which immunological tolerance was induced. Furthermore, this tg was only expressed in
CD11c+  cells  derived from the spleen,  lymph nodes as  well  as  the thymus (Zhang,  Zou
et  al.  2009).  Dresch et  al.  made use of  the DC-STAMP promoter  to  engineer  bone mar‐
row-targeted LVs. Therefore, ex vivo  transduced hematopoietic stem cells (HSC) were in‐
jected in lethally irradiated mice to make HSC chimeric animals (Dresch, Edelmann et al.
2008). When GFP expression was analyzed in the leukocyte population isolated from the
spleen,  the  main  DC  subpopulations  such  as  CD11b−CD8+  DCs,  CD11b+CD8−  DCs,  and
plasmacytoid DCs were GFP positive next to a small percentage of CD11c−CD11b+ mono‐
cytes.  Furthermore,  tg expression could only be detected in CD11c+  cells  in the thymus.
While  the  previous  two  tolerance  inducing  studies  could  be  explained  by  the  fact  that
undifferentiated  DC  precursors  were  transduced,  Kimura  et  al.  intravenously  injected
LVs encoding Trp2 driven by the  MHCII  promoter  and also  observed persistent  tg  ex‐
pression selectively in the CD11c, CD11b and CD19+  MHCII+  cells of the spleen without
CD8+  T  cell  responses  against  Trp2  in  contrast  to  a  CMV  carrying  construct  (Kimura,
Koya et al.  2007; Dresch, Edelmann et al.  2008). The induction of tolerance in this study
might be explained by the activation status of the transduced APCs. Induction of tg spe‐
cific  effector  T  cells  requires  fully  activated  APCs.  Since,  DC  activation  by  LVs  was
shown to  be  dose-dependent,  the  LV titers  used in  these  studies  could explain  the  tol‐
erogenic  instead of  stimulatory outcome (Breckpot,  Emeagi  et  al.  2007;  Breckpot,  Escors
et al. 2010).
Finally, also controllable or inducible tg expression can be a prerequisite. Reasons to use
tg regulation are:  to maintain appropriate levels of a gene product within the therapeu‐
tic range, to modulate, stop or resume tg expression in response to disease evolution, or
in response to an endogenous molecule as e.g. the secretion of insulin induced by hyper‐
glycemia.  For  human  gene  therapy,  several  ligand  dependent  transcription  regulatory
systems  have  been  developed.  For  clinical  applications,  such  systems  need  to  be  safe,
specific,  highly inducible,  reversible and only show dose dependent activation with low
basal  activity  while  their  ligands  need  to  be  bioavailable  and  low  in  immunogenicity
(Toniatti, Bujard et al. 2004). One of the first and most widely used ligands is Tetracylin
(Tet) or its more potent analog Doxycycline (Dox) (Efrat, Fusco-DeMane et al. 1995; Reis‐
er,  Lai  et  al.  2000).  In contrast  to the bacterial  lac repressor/operator or the Cre-loxP re‐
combinase system, it is applicable in vivo  and reversible (Deuschle, Hipskind et al.  1990;
Lakso,  Sauer  et  al.  1992).  The  original  bacterial  Tet  system is  based on a  Tet  repressor
protein (TetR)  that  inhibits  the expression of  the bacterial  Tet  resistance genes by bind‐
ing to cognate operator sequences (TetO) in their  regulatory regions.  Upon the addition
of Tet, the repressor is inactivated by allosteric change, allowing gene transcription (Gos‐
sen and Bujard 1992). The artificial Tet-off system is based on the generation of a hybrid
transactivator  (tTA)  by  fusion of  the  TetR to  the  transcription activation domain of  the
HSV VP16 protein. This fusion product will bind and activate transcription at promoters
that  include TetO while  the presence of  Dox impairs  this  binding,  resulting in the shut
off  of  gene expression (Furth,  St  Onge et  al.  1994)  (Figure 2A, adapted from (Ramezani
and  Hawley  2002).  In  contrast,  the  reverse  Tet  transactivator  (rtTA),  generated  by  ran‐
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dom mutagenesis  of  tTA,  requires  Dox to  bind to cognate  operator  sequences and acti‐
vate transcription resulting in the inducible Tet-on system (Figure 2B).
Figure 2. Representation of the artificial Tet-off (A) and Tet-on system (B). While the Dox binding transactivator
(tTA) binds to the tetracycline-responsive promoter element (TRE) and stimulates tg transcription in the absence of
Dox(A), the mutant reverse Tet-controlled transactivator (rtTA) binds to the TRE in the presence of Dox and stimulates
transcription(B).
However, the in vivo applicability of the Tet system remained limited due to leakiness and
insufficient induction levels. Therefore the Tet-on system has been optimized e.g. by isolat‐
ing novel rtTA variants and incorporating a Dox-dependent trans-silencer called tTS which
consists of the KRAB (Kruppel-Associated Box) trans-repressing domain of the human Kid-1
protein fused to the wild type TetR. This tTS has been used by the group of Szulc et al. to
develop a LV-based conditional gene expression system for drug-controllable expression of
inhibitory short hairpin RNAs (shRNAs), and reported on a robust and versatile system that
governed the tight control over the tg expression both in vitro as well as in vivo among oth‐
ers to generate transgenic mice (Szulc, Wiznerowicz et al. 2006). Moreover, Dox is orally bio‐
available, has a half-life of 14-22 hrs and has an excellent tissue penetration. Therefore
numerous groups have used both the Tet-on and Tet-off system within LV-based gene re‐
porter and therapeutic applications (Blomer, Naldini et al. 1997; Bahi, Boyer et al. 2004;
Blesch, Conner et al. 2005; Liu, Wang et al. 2008; Hioki, Kuramoto et al. 2009; Adriani, Boyer
et al. 2010). This is exemplified by a study of Seo et al. who developed an oncolytic LV-
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mediated Tet-on inducible system based on co-transduction of two LVs to drive the expres‐
sion of a pro-apoptotic gene by the promoter of matrix-metalloproteinase-2 (MMP-2), which
is highly expressed in several cancer cell lines. The first LV expressed a rtTA under the con‐
trol of the MMP-2 promoter, whereas the second LV expressed the pro-apoptotic gene Bax,
under the control of the tetracycline-responsive element (Seo, Kim et al. 2009). While most
Dox inducible systems are based on the co-transduction of two LVs, all-in-one vectors have
also been described recently (Ogueta, Yao et al. 2001; Barde, Zanta-Boussif et al. 2006; Her‐
old, van den Brandt et al. 2008; Wiederschain, Wee et al. 2009; Benabdellah, Cobo et al.
2011). Furthermore, an extra Dox-regulated system based on the original TetR protein was
developed in 1998. It serves as an alternative to the tTA- and rtTA-based systems because
the latter were accompanied by secondary effects due to expression of the transactivator do‐
mains. Benabdellah et al. made use of the Dox-responsive cassette driving the expression of
eGFP and the SFFV promoter expressing high amounts of the TetR protein in an all-in one
vector system. This LV efficiently produced Dox-regulated cell lines, including primary hu‐
man fibroblasts and human mesenchymal stem cells. However, a major concern using Dox
remains the possibility to develop resistance to the antibioticum Tet, and although it seems a
non-immunogenic system in several mouse strains, studies with intramuscularly delivered
Tet-on activators in non-human primates did elicit a cellular and humoral response (Latta-
Mahieu, Rolland et al. 2002).
Besides the Tet on/off systems, a plethora of inducible systems has been examined both in
vitro and in vivo. An interesting strategy is based on the use of small molecules with distinct
binding surfaces for two different polypeptides to modulate the activity of dimerizer-regu‐
lated systems. The prototype molecule is rapamycin, which mediates the heterodimer for‐
mation between two molecules (FK506-binding protein and FKBP rapamycin binding) that
are coupled to a DNA binding domain (DBD) and transcription activation domain (AD) re‐
spectively (Pollock, Issner et al. 2000). The rapamycin inducible system has low basal activi‐
ty because of the physical separation of the DBD and AD molecules, the ligand has a short
half-life of about 4.5 hrs although the induced gene expression lasts for days due to the
strong stability of the DBD-AD assembled complex (Toniatti, Bujard et al. 2004). Tian et al.
used a variant of this system to engineer LVs that produce a fusion protein between the fur‐
in-cleavable proinsulin and the self-dimerization mutant of FK506-binding protein to yield
bioactive insulin in keratinocytes. Epidermal keratinocytes in culture, in stratified bioengi‐
neered epidermis as well as implanted in diabetic athymic mice released insulin within max‐
imally 1 hr after addition of rapamycin. Secretion slowed or stopped within 2-3 hrs after
removal of the inducing agent. Even in diabetic animals with severe hyperglycemia, de‐
creased serum glucose levels to normal levels were reported (Tian, Lei et al. 2008). The ma‐
jor disadvantage of this technique is the immunosuppressing activity of rapamycin and the
only partial oral availability, which renders this system impractical for clinical applications.
Another strategy is based on the fact that heterologous proteins can be made hormone re‐
sponsive by fusing them with the hormone-binding domain of steroid receptors. The best-
characterized system is regulated by mifepristone or RU486, a synthetic progesterone
antagonist. Prototypically the RU486-binding chimera known as GeneSwitch® consists of the
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GAL4 DBD from Saccharomyces cerevisiae fused to the ligand-binding domain of a mutant
progesterone receptor and the activation domain of the p65 subunit of human NF-κB
(Abruzzese, Godin et al. 2000; Sirin and Park 2003). Upon ligand binding the GeneSwitch®
protein binds to GAL4 upstream activating sequences in the promoter driving the expres‐
sion of the tg of interest. An advantage of the GeneSwitch® system is that the majority of its
components are modified human proteins with no impact on cell viability. Furthermore, us‐
age of a mifepristone-inducible (auto-inducible) promoter to regulate expression of the chi‐
meric transactivator dramatically reduced basal expression of the tg in the absence of the
inducer, thereby improving the dynamic range of in vivo tg regulation (Shinoda, Hieda et al.
2009). In addition, although mifepristone has anti-progesterone and -glucocorticoid activi‐
ties, the concentration needed for ligand-inducible transactivation of the target gene is much
lower than the concentration producing an anti-progesterone effect in humans. However, it
is thought that the lower dosage may still affect the ovarian cycle and exert a contraceptive
activity. Therefore the search for other inducers that are unable to interact with endogenous
progesterone would be more appropriate for clinical use (Sarkar 2002). As an alternative ste‐
roid-receptor based inducible system, the glucocorticosteroid responsive element (GRE5)
was cloned into a LV (LV-GRE-IL10) encoding interleukin-10 (IL-10). Expression of IL-10 by
LV-GRE-IL-10 appeared rapidly, was sustained and inducible in both ovine and human cor‐
neas in the presence of dexamethasone (Parker, Brereton et al. 2009). Another alternative can
be the steroid hormone ecdysone, which plays a fundamental role during insect molting and
metamorphosis. Ecdysteroids are considered safe because they are found in large amounts
as phytoecdysteroids in vegetables, present in the human diet without detrimental effects.
Mouse hematopoietic progenitors transduced with LVs containing an ecdysone-regulated
GFP expression cassette efficiently turned GFP expression on and off in transplanted ani‐
mals with low basal activity (Xu, Mizuguchi et al. 2003; Galimi, Saez et al. 2005). Possibly,
several other systems will be developed to control tg expression after LV transduction. Po‐
tential systems could be based on the cell-cell communication quorum sensing process
(Neddermann, Gargioli et al. 2003) or the naturally evolved mechanisms of antibiotic resist‐
ance to pristinamycin, a composite streptogramin antibiotic or erythromicin, a member of
the macrolide antibiotics (Fussenegger, Morris et al. 2000; Roberts 2002).
3. microRNA detargeting
Recently, the concept of microRNA (miRNA) mediated post-transcriptional tg regulation
was introduced in LV-based targeting. miRNAs are 21-22 nucleotide long non-coding frag‐
ments which are partially or extensively complementary to an endogenous mRNA molecule
(Lai 2002). In mammals, over 400 different miRNAs have been identified so far, most of
which are well conserved among species ranging from plants, worms, insects to humans
(Brown and Naldini 2009). Some of these miRNAs are expressed ubiquitously whereas oth‐
ers are only expressed at certain developmental stages or in a certain cell type. Upon bind‐
ing of a miRNA molecule to its complementary target sequence, repression of translation or
direct destruction of the mRNA is induced. The detailed mechanisms involved in this post-
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transcriptional regulation process, do not lie within the scope of this book chapter but are
reviewed elsewhere (Nelson, Kiriakidou et al. 2003; Bartel 2004). A brief description together
with a schematic representation is depicted in Figure 3 (adapted from http://www.micro‐
rna.ic.cz/mirna4.html).
Figure 3. miRNA-based post-transcriptional gene silencing. Briefly, endogenous miRNA genes are transcribed by
RNA polymerase II to pri-miRNA precursor molecules in the nucleus. These are processed to pre-miRNA by a special‐
ized enzymatic pathway called Pasha/Drosha and will release the pre-miRNA in short hairpin RNA (shRNA). Then,
these pre-miRNAs are exported to the cytoplasm where Dicer degrades most of the shRNA, leaving a miRNA duplex
which is loaded onto the AGO complex (Argonaut), forming the preRISC (RNA Interference Silencing Complex). Subse‐
quently the miRNA strand is degraded, leaving its complementary miRNA intact within the RISC complex. Then, this
complex scans mRNAs and when complementation is found, the mRNA is degraded or the poly-A tail is removed,
leading to mRNA destabilization or stalled mRNA translation.
In order to limit undesired vector tg expression, LVs encoding target sequences of endoge‐
nous miRNAs have been developed. By incorporating at the 3 ’UTR region of the expression
cassette one or more copies of a sequence that is perfectly complementary to a miRNA (miR‐
NA tagging), the transgenic mRNA will be degraded or repressed in cells where the comple‐
mentary miRNA is expressed. This new way of controlling tg expression at the level of the
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mRNA product came as a complementary strategy to transcriptional targeting since the lat‐
ter is associated with some disadvantages such as: (1) difficulty to identify and faithfully re‐
constitute a gene’s promoter; (2) for integrating LVs, promoters and enhancers can be
trapped, leading to aberrant expression (De Palma, Montini et al. 2005), (3) transcription can
be promiscuous and (4) only few genes have truly cell-specific transcriptional patterns while
several promoters are active in many different cell types or states. Moreover, as miRNAs
regulate expression at the post-transcriptional level, copy number and vector integration site
have no appreciable effect on their regulation, which ensures consistent control throughout
the transduced cell population.
Successful outcomes of LV-based gene therapy have long been precluded by the develop‐
ment of tg-specific immunity as a consequence of the direct expression of the tg product by
professional APCs. Therefore Brown et al. challenged mice with LVs encoding a target se‐
quence for miRNA-142-3p, a microRNA specifically expressed in the hematopoietic lineag‐
es. Upon injection, they demonstrated a 100-fold suppression of reporter gene expression in
intravascular and extravascular hematopoietic lineages, including APCs (Brown, Venneri et
al. 2006). One year later, its usefulness was evidenced by the miRNA-142-3p regulated LV
mediated stable correction of hemophilia B in mice (Brown, Cantore et al. 2007). Its expres‐
sion leads to reduced tg expression in APCs and subsequently lower anti-tg immune re‐
sponses. Moreover it was demonstrated that in vivo delivery of this post-transcriptionally
regulated LV induced tg-specific Foxp3+ regulatory CD4+ T cells, which promoted immuno‐
logic tolerance (Annoni, Brown et al. 2009 ). Curiously, they also reported the necessity of a
hepatocyte specific promoter for this immunological tolerance. So, these studies showed the
impressive potential of miRNA-based detargeting to overcome a major hurdle for clinical
gene therapy, however also other factors than tg expression in APCs seem to influence the
immunological outcome of a gene transfer procedure. Examples are the type of vector used,
the tissue targeted and the presence of inflammation (Brown and Lillicrap 2002; Cao, Furlan-
Freguia et al. 2007).
Another reason to pursue stringent tg regulation, is to express the tg in a specific develop‐
mental state. Brown et al. showed that multiple endogenous miRNAs can be used to achieve
tg expression patterns that rapidly adjust and sharply discriminate among the myeloid and
lymphoid lineage in therapeutically relevant HSCs and their progeny with miRNA-223, or
among immature and mature APCs using miRNA-155 (Brown, Gentner et al. 2007). Another
example is provided by Gentner et al. who used the miRNA-126 target sequence to detarget
tg expression from stem cells and progenitors from the hematopoietic cell lineage in order to
avoid expression of the highly toxic GALC in these stages, while inducing GALC expression
in mature cells from the hematopoietic lineage to correct globoid cell leukodystrophy (Gent‐
ner, Visigalli et al. 2010). Furthermore the group of Sachdeva et al. used miRNA-292 regulat‐
ed LVs to visualize and segregate differentiating neural progenitors in pluripotent cultures
and demonstrated that miRNA-regulated vectors allow a potentially broad use on stem cell
applications (Sachdeva, Jonsson et al. 2010). Finally, Sadelain et al. used LVs that encode an‐
tigen specific receptors together with target sites for miRNA-181a to suppress the expression
of the receptor in late thymocytes. This avoided clonal deletion of antigen specific T cells in
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the thymus and subsequent challenge with antigen expressing tumors did not result in tu‐
mor growth (Papapetrou, Kovalovsky et al. 2009).
Furthermore this technology is useful as a mechanism to increase vector safety and efficacy
by limiting the expression of a toxic or pro-apoptotic tg to certain target cells. For example
Lachmann et al. used the miRNA-150 target sequence to suppress GFP expression in lym‐
phocytes and thereby prevented tg-induced lymphotoxicity (Lachmann, Jagielska et al.
2011). On the other hand unrestrained growth of transduced cells could also be avoided us‐
ing miRNA-based detargeting when growth-promoting gens are replaced (Hawley, Fong et
al. 1998). Moreover, miRNA-based regulation could be desirable when targeted gene expres‐
sion is needed to assess the contribution of a particular cell type to physiological processes
or for the development of new therapeutic strategies. This is exemplified by the work of Col‐
in et al. who segregated tg expression between neurons and astrocytes following injection
into the brain by exploiting the activity of miRNA-124 (Colin, Faideau et al. 2009). Another
miRNA-based targeting strategy developed a few years ago was the concept of miRNA
sponges, decoys, erasers, antagomirs or knockdowns (Ebert, Neilson et al. 2007; Scherr, Ven‐
turini et al. 2007; Gentner, Schira et al. 2009). Therefore vectors expressing miRNA target
sites can effectively saturate an endogenous miRNA and prevent it from regulating its natu‐
ral targets. This technology enables a new way of investigating miRNA biology and has al‐
ready been used to study the role of miRNAs in cancer, cardiac function and hematopoiesis
(Scherr, Venturini et al. 2007; Bonci, Coppola et al. 2008; Kumar, Erkeland et al. 2008; Sayed,
Rane et al. 2008; Gentner, Schira et al. 2009; Valastyan, Reinhardt et al. 2009).
A possible concern of miRNA-based detargeting is whether sufficient target knockdown can
be achieved for specific applications without escape mutants arising (Kelly, Hadac et al.
2008). In addition, it is highly likely that overexpression of the synthetic target sites will sat‐
urate their corresponding endogenous miRNAs and deregulate expression of natural targets
with deleterious consequences. However, the latter has not been reported so far (Brown,
Gentner et al. 2007). Moreover, miRNA-based regulation is a very robust system since at low
copy vector number miRNA regulation of tg expression remains effective. Apparently,
when a threshold miRNA concentration is present, the tg will be suppressed. This robust‐
ness can probably be explained by the perfect complementarity of the target sequence and
the endogenous miRNA sequence. Indeed, when imperfectly complementary sites were
used, this did result in a detectable decrease in target suppression, although only at very
high vector copy numbers. So, although it should be recognized that the knowledge regard‐
ing miRNA biology and function is still limited, this strategy holds great potential to care‐
fully move towards clinical translation (Brown and Naldini 2009)
4. Transductional targeting
Although the strategies described above demonstrate cell-specific gene expression, they of‐
ten require broad tropism LVs which does not reduce the risk for RCL formation or inser‐
tional mutagenesis. Therefore transductional targeting of LVs seems a more interesting
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strategy to tackle both safety and efficacy concerns. The concept of swapping the viral enve‐
lope proteins of different viral species is called pseudotyping. Already in 1979, the envelope
glycoprotein of the avian retrovirus was used to pseudotype VSV virions in order to selec‐
tively enrich for VSV temperature-sensitive mutants of VSV.G biosynthesis (Lodish and
Weiss 1979). Later it was shown that wild type HIV-1 particles which were produced in cells
that were infected with another virus, e.g. murine leukemia virus (MLV) or VSV, led to the
generation of phenotypically mixed virions with an expanded host range (Canivet, Hoffman
et al. 1990; Zhu, Chen et al. 1990). These observations introduced the concept of pseudotyp‐
ing and in the early 90’s the gp160 sequence of a replication defective HIV-1 derived LV was
replaced by a MLV gp (Page, Landau et al. 1990). Later on the natural envelope gp from an
MLV-based vector was replaced with the viral attachment protein of VSV (Emi, Friedmann
et al. 1991; Burns, Friedmann et al. 1993). Today, most synthetic LVs are pseudotyped with a
heterologous envelope protein to increase their stability, infectivity and safety. Notably, the
first LVs were not pseudotyped but displayed the native HIV-1 envelope protein at their
surface. This limited their tropism to CD4-expressing cells (Dropulic 2011). Interestingly,
VSV.G pseudotyped vectors are more stable than their natural counterparts. This allows
concentration to higher titers by ultracentrifugation and confers broad tropism, as VSV.G
binds to a still unknown ubiquitous membrane component (Cronin, Zhang et al. 2005). This
superior transduction efficiency comes in handy for the treatment of genetic disorders such
as β-thalassemia and X-linked adenoleukodystrophy (Cartier, Hacein-Bey-Abina et al. 2009;
Cavazzana-Calvo, Payen et al. 2010). Nonetheless, VSV.G pseudotyped LVs also present
several downsides. Firstly, the VSV gp is cytotoxic when expressed constitutively at high
concentrations, which impedes the production of stable packaging cell lines (Lopes, Dewan‐
nieux et al. 2011). In addition, cytotoxicity associated with VSV.G pseudotyped LVs has
been observed when in vivo administered at high concentration, in comparison with other
pseudotypes (Watson, Kobinger et al. 2002). Another critical hurdle for systemic delivery us‐
ing VSV.G pseudotyped LVs is their susceptibility to neutralization by human serum com‐
plement, although this can be bypassed by polyethylene glycol-modification (PEGylation) of
the virions (DePolo, Reed et al. 2000; Croyle, Callahan et al. 2004).
An ever-growing list of alternative pantropic as well as ecotropic naturally occurring gps
has been evaluated for LV pseudotyping. These vary in origin, tropism, titer, stability, effi‐
ciency of packaging, inactivation by complement, efficiency of cell transduction and induc‐
tion of an immune response (Cronin, Zhang et al. 2005). They can be of retroviral origin such
as those from T-lymphotropic virus, maedi-visna virus, MLV, feline endogenous retrovirus
and gibbon ape leukemia virus (GALV) (Rasko, Battini et al. 1999; Stitz, Buchholz et al. 2000;
Zeilfelder and Bosch 2001; Strang, Ikeda et al. 2004; Sakuma, De Ravin et al. 2010). In gener‐
al, LVs pseudotyped with a γ-retroviral envelope transduce CD34+ hematopoetic precursors,
a property that has been used for the correction of X-linked severe combined immunodefi‐
ciency (SCID) using the GALV or MLV-A envelopes (Cavazzana-Calvo, Hacein-Bey et al.
2000; Gaspar, Parsley et al. 2004). Nonetheless, envelope gps of numerous non-retroviral
families have been used as well to pseudotype LVs. A first example is provided by the Toga‐
viridae family, where their envelope gps (from alphaviruses such as the Ross River virus)
equips the LV with a mouse and human DC-specific tropism when injected intravenously
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(Strang, Takeuchi et al. 2005), and with an astrocyte and oligodendrocyte specific tropism
when injected into the mouse brain (Kang, Stein et al. 2002). Another example is provided
by the family of the Baculoviridae where the gp64 gp ensures high particle stability in addi‐
tion to a hepatocyte specific tropism (Matsui, Hegadorn et al. 2011). LVs pseudotyped with
the lymphocytic choriomeningitis virus (LCMV) envelope from the Arenaviridae preferential‐
ly transduce cells from the central nervous system such as neural stem cells and progenitor
cells, and also to glioma cells and insulin secreting β-cells (Kobinger, Deng et al. 2004; Milet‐
ic, Fischer et al. 2004; Stein, Martins et al. 2005). As there is an increasing interest in the de‐
velopment of gene therapeutic strategies for malignant gliomas, the most frequent primary
brain tumors with very poor prognosis, several groups report on the use of LCMV gp pseu‐
dotyped LVs to target almost exclusively astrocytes, the main source of malignant glioma
cells (Beyer, Westphal et al. 2002; Miletic, Fischer et al. 2004; Steffens, Tebbets et al. 2004).
The H and F envelope proteins from the Paramyxoviridae family, such as those derived from
measles viruses, provide LVs with the capacity to bind to SLAM and CD46, which confers
efficient virus entry, nuclear transport and integration in non-activated B and T lympho‐
cytes. This property is particularly important, since primary unstimulated B and T cells are
generally difficult to transduce if not pre-treated to induce progression through the cell cy‐
cle (e.g. through stimulation with anti-CD3/anti-CD28 antibodies or cytokines) (Frecha, Levy
et al. 2010; Frecha, Levy et al. 2011). To transduce airway epithelial cells efficiently, envelope
proteins from several viruses that infect respiratory tissues or cells have been evaluated. For
efficient transduction of unconditioned airway epithelial cells from the apical side, enve‐
lopes derived from the ebola virus (Filoviridae), members of the Paramyxoviridae such as the
respiratory syncytial (RSV) and sendai viruses, and members of the Orthomyxoviridae such as
the influenza and fowl plaque viruses have been evaluated (Kobinger, Weiner et al. 2001;
Nefkens, Garcia et al. 2007; Mitomo, Griesenbach et al. 2010). Surprisingly, it has been re‐
ported that the S protein of the severe acute respiratory syndrome-associated coronavirus
(Coronaviridae) mediates entry into hepatoma cell lines (Hofmann, Hattermann et al. 2004).
Finally, although the vesicular stomatitis, mokola and rabies virus are all derived from the
Rhabdoviridae family, only LVs pseudotyped with the rabies-G envelope enable retrograde
transport to motoneurons of the spinal cord upon intramuscular injection or to the thalamus
upon striatal injection. In contrast, VSV.G displaying LVs transduce cells only locally while
mokola-pseudotyped LVs preferentially target non-neuronal glial cells (Mazarakis, Azzouz
et al. 2001; Azzouz, Ralph et al. 2004; Wong, Azzouz et al. 2004; Colin, Faideau et al. 2009;
Calame, Cachafeiro et al. 2011).
Although the use of an existing viral envelope gp seems the most straightforward way to
pseudotype LVs, a natural variant with the desired delivery properties is not available for
every therapeutic application. Moreover, natural gps can come with limitations such as sen‐
sitivity to neutralization by the host immune response, lack of specificity and/or insufficient
transduction efficiency. Also their production and purification can be inefficient (Schaffer,
Koerber et al. 2008). Therefore, the development of LVs with customized, user-defined gene
delivery properties by molecular engineering of the envelope gps is an alternative strategy
to retarget the LV to specific cell-surface receptors. This molecular engineering has become a
collective term for many different strategies, which will be described below.
Targeted Lentiviral Vectors: Current Applications and Future Potential
http://dx.doi.org/10.5772/52770
357
A first strategy to alter the tropism of a virally derived gp is by rational point and domain
mutagenesis. This is exemplified by the DC-specific targeting strategy from Yang et al. Cer‐
tain subsets of DCs carry the DC-SIGN protein (also known as CD209) on their surface,
which is a C-type lectin-like receptor that potentiates rapid binding and endocytosis of ma‐
terials. The sindbis virus envelope gp consists of two integral membrane gps that form a het‐
erodimer and function as one unit. The fusogenic monomer is E1 and needs binding via E2
to mediate low pH-dependent fusion. The latter binds to the DC-SIGN receptor, next to the
canonical viral receptor heparin sulfate, expressed by many cell types. Since both protein
binding sites are physically separated, selective mutation at the E2 monomer is possible, ab‐
rogating the heparin sulfate binding part while leaving the DC-SIGN binding part intact. By
pseudotyping a LV with this mutated sindbis virus derived envelope gp, targeted infection
of DCs in vivo after direct subcutaneous administration was achieved. Moreover, this elicit‐
ed a strong antigen-specific immune response (Yang, Yang et al. 2008; Hu, Dai et al. 2010).
Another example is the substitution of the V3-loop region of the SIV envelope gp with the
corresponding region of a T cell tropic HIV-1 to create a T-cell targeted MLV vector, pseudo‐
typed with this engineered SIV gp (Steidl, Stitz et al. 2002). A final example is provided by
Dylla et al. who diminished the alfa-dystroglycan affinity of the LCMV WE45 strain enve‐
lope gp by a point mutation. When a FIV derived LV was pseudotyped with this point mu‐
tated LCMV gp, their intravenous injection in adult mice yielded low transduction
efficiencies in hepatocytes in contrast to abundant liver and cardiomyocyte transduction
with the wild type LCMV gp pseudotyped FIVs (Dylla, Xie et al. 2011).
Apart from genetic alterations, chemical modifications can also alter LV tropism. PEGyla‐
tion of VSV.G pseudotyped LVs is one such example where the LVs’ tropism is not altered.
Nevertheless, chemical modifications can lead to targeted gene delivery vehicles, for exam‐
ple by tagging the MLV vector with galactose to selectively transduce human hepatoma cell
lines expressing asialo-gp receptors specific for oligosaccharides with terminal galactose res‐
idues (Neda, Wu et al. 1991). Furthermore, Morizono et al. reported the production of LVs
pseudotyped with sindbis virus gps in the presence of deoxymannojirimycin. This modifica‐
tion altered the structures of N-glycans from complex to high mannose structures as it inhib‐
its mannosidase. This led to DC-SIGN specific binding although the gps were genetically
modified to prevent interaction with DC-SIGN (Morizono, Ku et al. 2010). Furthermore it
was demonstrated that binding of sindbis virus gp to DCs is directly related to the amount
of high-mannose structures on the gp (Tai, Froelich et al. 2011). Unfortunately, the effective‐
ness of the chemically modified particles strongly depends on the reaction conditions of the
applied modifications.
Other chimeric envelope gps can be generated by covalently fusing a short peptide, a ligand
or an antibody to an envelope gp. The advantages of short peptides are that they don’t se‐
verely disrupt the original envelope gps’ function and that via high-throughput library ap‐
proaches, targeted peptides with strong binding affinity and unlimited specificity within the
context of a particular gp can be generated (Schaffer, Koerber et al. 2008). However, they can
hinder multimerisation of capsid monomers, create fusion products with lower thermosta‐
bility and hinder proper intracellular trafficking of the gp during viral production. The latter
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is exemplified by the blockage in trafficking in the producer cells to the plasma membrane
of VSV.G when linked to a collagen-binding motif (Guibinga, Hall et al. 2004). Different
kinds of ligands such as cytokines and growth factors have been linked to the amino-termi‐
nal region or receptor-binding domain of the envelope gp, most often derived of MLV. This
is amongst others exemplified by fusion of the MLV gp to hepatocyte growth factor to target
the LV to hepatocytes (Nguyen, Pages et al. 1998), or to the insulin-like growth factor (IGF-I)
(Chadwick, Morling et al. 1999). Interestingly, these ligands can elevate the transduction ef‐
ficiency by altering the targets’ physiological state. When the fusion product of the MLV gp
and IL-2 is used to pseudotype LVs, a 34-fold higher infection efficiency was observed of
quiescent IL-2 receptor expressing cells compared to LVs pseudotyped with the wild type
MLV gp. This was explained by IL-2 induced activation of the cell cycle from the otherwise
barely transducible quiescent cells (Maurice, Mazur et al. 1999). However, a very low to un‐
observable transduction profile is often reported which can be attributed to sequestration of
the LV particles at the target cell surface, directing the viral particle to a degradation path‐
way after endocytosis and/or inability of the fusion product to trigger a conformational
change essential for viral fusion and subsequent infection (Lavillette, Russell et al. 2001; Ka‐
tane, Takao et al. 2002). In addition to peptides and ligands, also antibodies and their deriva‐
tives can be used. In general, single chain variable fragments or scFvs offer higher specificity
than short peptides but as they are larger in size, the chance that they disrupt the process of
conformational changes of the gp to mediate membrane fusion increases. Therefore scFvs
are most often linked to a spacer peptide that permits proper conformation of both the scFv
domain and the envelope gp as exemplified by the fusion of the MLV gp to a scFv against
MHC class I (Karavanas, Marin et al. 2002). For LV targeting to APCs, several attempts have
been made to couple an anti-MHC class II scFv to an ecotropic gp such as MLV or VSV.G
(Dreja and Piechaczyk 2006; Gennari, Lopes et al. 2009). Recently, the use of DARPins or de‐
signed ankyrin repeat proteins has been reported. These can be fused to the H protein of
measles virus for example and then be co-displayed with the fusogenic F protein on the sur‐
face of the LV. The advantage is that DARPins can be selected to become high-affinity bind‐
ers to any kind of target molecule thus this seems a promising alternative to scFvs for
retargeting LVs (Munch, Muhlebach et al. 2011). So, in general, the use of chimeric envelope
proteins for LV targeting has proven to offer tremendous opportunities but at the same time
to be a challenge as the function of chimeric gps is often severely compromised which leads
to a very inefficient transduction profile (Fielding, Maurice et al. 1998; Dreja and Piechaczyk
2006; Waehler, Russell et al. 2007; Buchholz, Duerner et al. 2008).
Several solutions have been created to circumvent the problems associated with the forma‐
tion of conformational dysfunctional fusion products. One solution is the inclusion of a pro‐
tease cleavable peptide between the gp and the ligand. This is certainly an interesting
strategy for the targeting of tumor cells, as they secrete MMP, which degrade the extracellu‐
lar matrix to metastasize. By linking a proline-rich hinge and an MMP cleavage site to the
fusion product of a scFv recognizing carcinoembryonic antigen (CEA) and the MLV gp, se‐
lective targeting of CEA-positive cells after in vivo injection of producer cells at the tumor
site was observed (Chowdhury, Chester et al. 2004). Taking this hinge region idea one step
further, the concept of ‘molecular bridges’ was introduced where a bispecific linker mole‐
Targeted Lentiviral Vectors: Current Applications and Future Potential
http://dx.doi.org/10.5772/52770
359
cule recognizes both the viral gp as well as the molecular determinant on the target cell. This
concept is based on a bridging system that was introduced more than 20 years ago and
where three different linker molecules were involved: two biotinylated antibodies that
bound the MLV gp and MHC class I or II proteins on the target cells respectively, and a
bridging streptavidin molecule linking both antibodies. This led to the generation of a MLV
that was capable of transducing MHC class I and II expressing cells (Roux, Jeanteur et al.
1989). Subsequently, two-protein molecular bridges have been exploited based on the avi‐
din-biotin system. A recent example is provided by O’Leary et al. who used a detoxified re‐
combinant form of the full-length botulinum neurotoxin, fused to core streptavidin that for
its part was coupled to a biotinylated LV. This envelope gp construct endowed the LV parti‐
cle with considerable neuron selectivity in vitro as well as in vivo after injection into the tra‐
chea (O'Leary, Ovsepian et al. 2011). Nowadays, alternative linkers such as ligand-receptor,
chemical conjugations and monoclonal antibodies have been exploited to retarget LVs as
well (Roux, Jeanteur et al. 1989; Boerger, Snitkovsky et al. 1999). For the latter, the E2 protein
of the sindbis gp has been modified to contain the Fc-binding domain (ZZ domain) of pro‐
tein A, making it possible to bind to a monoclonal antibody specific for a target molecule via
its Fab antigen recognition end (Morizono, Xie et al. 2005). However, doubts are raised
about the affinity of the adaptor-virus complex, as this may not be sufficient to prevent dis‐
sociation within the patient’s blood. Moreover, complexity ascends as both the virion as the
adaptor must be produced, purified and fully characterized for clinical approval. Another
alternative possibility is to co-display a chimeric envelope gp together with a wild type gp
such as VSV.G to enhance the transduction efficiency (Maurice, Verhoeyen et al. 2002; Ver‐
hoeyen, Dardalhon et al. 2003; Verhoeyen, Wiznerowicz et al. 2005). However, this had also
limited success due to partial loss of targeting specificity. Therefore, a final alternative is the
usage of a mutated fusogenic but binding-defective envelope gp to mediate fusion upon
binding by the chimeric gp. The group of Lin et al. co-expressed the MLV gp fused to solu‐
ble Fms-like tyrosine kinase 3 (Flt3)-ligand together with a binding-defective influenza he‐
magglutinin protein from the fowl plague virus rostock 34 (HAmu). When LVs were
pseudotyped with both of these gps, Flt3-targeted transduction was enhanced when com‐
pared to LVs without HAmu and could be competed away by the addition of soluble Flt3-
ligand (Lin, Kasahara et al. 2001). Another more straightforward strategy is the use of the
E1/E2 heterodimer gp of sindbis virus as the fusion and binding functions are already sepa‐
rated over two different monomers. By mutating the binding E2 monomer, its binding prop‐
erty can be completely abolished. Therefore, this binding defective E2 protein forms an ideal
scaffold for cell-specific antibody conjugation to confer specific tropism to an endless list of
cell types such as P-gp-expressing melanoma progenitor cells and endothelial cells (Morizo‐
no, Xie et al. 2005; Pariente, Mao et al. 2008). A drawback is that they only induce fusion
upon low pH. Therefore alternatives were explored such as the H and F protein of the mea‐
sles virus, which induce fusion without the need for endocytosis (Earp, Delos et al. 2005;
Funke, Schneider et al. 2009). This is exemplified by a study were a binding defective form
of the H protein was fused to a CD20 specific scFv to pseudotype LVs. When these LVs were
used to kill cells in culture, they selectively killed the CD20+ human lymphocytes in co-cul‐
ture with CD20- cells. This demonstrated the ability of these LVs to exclusively transfer a po‐
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tentially hazardous therapeutic protein into targeted cell populations with virtual absence of
background transduction in non-target cells (Funke, Maisner et al. 2008). Meanwhile, a
broad variety of surface antigens has been successfully targeted using this strategy (Blechacz
and Russell 2008)
A fourth strategy to target LVs is based on two concepts: (1) the separation of binding and
fusion functions over two distinct envelope molecules and (2) the ability of LVs to incorpo‐
rate host cell proteins into their envelope as they bud from the plasmamembrane of their
producer cells (Chandrashekran, Gordon et al. 2004; Kueng, Leb et al. 2007). Chandrashek‐
ran et al. reported on efficient and specific targeting to human cells expressing stem cell fac‐
tor (SCF) receptor (c-kit) by an ecotropic gp pseudotyped LV which also displayed surface
SCF. Another example is the overexpression of the HIV-1 derived primary receptor CD4 and
fusogenic co-receptor CXCR4 or CCR5 on the membrane of producer cells. From these cells,
LVs were generated that infect HIV-1 envelope gp expressing cells next to cells infected with
HIV-1, enabling the development of novel antiviral therapy approaches (Somia, Miyoshi et
al. 2000). Since the transduction efficiency was relatively low, LV co-enveloped with the
HIV-1 cellular receptor CD4 and the E2 protein from sindbis virus were created. These
turned out to have a higher infectivity level than in the former strategy (Lee, Dang et al.
2011). In another study the binding defective but fusogenic E1/E2 heterodimer was used to
be co-displayed with a separate membrane bound anti-CD20 antibody in order to transduce
exclusively CD20+ B cells (Lei, Joo et al. 2009). Today, numerous examples are found that ap‐
ply this principle to target the following: immunoglobulin-expressing B cells, CD3+ T cells
and CD117+ HSCs (Ziegler, Yang et al. 2008; Froelich, Ziegler et al. 2009; Yang, Joo et al.
2009). However, clinical applications with LVs displaying scFvs are hampered by lack of sta‐
bility, size and immunogenicity leading to the development of neutralizing antibodies. To
solve these problems, we developed the Nanobody (Nb) display technology (Goyvaerts, De
Groeve et al. 2012). In this strategy, a fusogenic but binding-defective form of VSV.G
(VSV.GS) (Zhang, Kutner et al. 2010) is co-displayed with a surface bound form of a cell-spe‐
cific Nb to confer target binding (Figure 4). Some twenty years ago, Hamers-Casterman et al.
discovered that part of the humoral response of Camelids is based on a unique repertoire of
antibodies, which only consisted of two heavy chains (Hamers-Casterman, Atarhouch et al.
1993). The antigen binding part of these antibodies is composed of only one single variable
region, termed VHH or Nb. These Nbs have unique characteristics and offer many advan‐
tages over scFvs to target LVs to specific cell types. These include (1) they are highly soluble,
(2) they can refold after denaturation whilst retaining their binding capacity, (3) cloning and
selection of antigen-specific Nbs obviate the need for construction and screening of large li‐
braries, (4) as Nbs can be fused to other proteins, it is possible to present them on the cell
membrane of a producer cell line, thus generating LVs that incorporate a cell-specific Nb in
their envelope during budding. Using the Nb display technology, we demonstrated produc‐
tion of stable Nb pseudotyped LV stocks at high titers with a DC subtype specific transduc‐
tion profile both in vitro as well as in vivo (Goyvaerts, De Groeve et al. 2012). As ligand
specific Nbs can be generated to potentially every cell surface molecule, this technology will
be applicable to target LVs to every cell type for which cell specific surface molecules are
characterized (Gainkam, Huang et al. 2008; Vaneycken, Devoogdt et al. 2011).
Targeted Lentiviral Vectors: Current Applications and Future Potential
http://dx.doi.org/10.5772/52770
361
The downside of the use of the above-described strategies is that they rely on the fusogenic
capacity of a gp that is derived from viruses infectious to humans such as VSV, measles vi‐
rus, sindbis virus and MLV. Their exposure to the complement or immune system, leading
to anti-gp antibodies, might limit their clinical applicability. To surmount these obstacles,
Frecha et al. pseudotyped LVs with a mutant fusogenic gp derived from an endogenous fe‐
line virus, named RD114. The mutant RD114 gp is an attractive candidate for in vivo use as it
is resistant to degradation by the human complement. By co-displaying the early-acting-cy‐
tokine SCF together with mutant RD114 gp, human CD34+ HSCs could be targeted in vivo
(Frecha, Fusil et al. 2011; Frecha, Costa et al. 2012). SCF was responsible for a slight and tran‐
sient stimulation of the HSCs while preserving the ‘stemness’ of the targeted HSCs. In that
way, the need for CD3/CD28 or cytokine pretreatment was obviated. Springfeld et al. recent‐
ly pseudotyped LVs with the H and F gps of the Tupaia paramyxovirus (TPMV), an animal
virus without close human pathogenic relatives. Moreover, as this virus does not infect hu‐
man cells, detargeting the H protein from its natural receptors is unnecessary. When LVs
were pseudotyped with the TPMV envelope protein linked to an anti-CD20 single chain an‐
tibody, selective transduction of CD20+ cells, including quiescent primary human B cells,
was reported (Enkirch, Kneissl et al. 2012).
Figure 4. Principle of the Nb display technology. The Nb display technology is based on the fact that LVs need to
bind and fuse with the membrane of a target cell for proper infection. While VSV.G accounts for both of these func‐
tions, we propose to separate these functions over two different molecules: (1) binding via a membrane bound Nb
against the target cell of choice and (2) fusion via VSV.GS, which is a binding defective truncated version of VSV.G.
Recently an innovative alternative strategy has been described by Mannell et al. for site spe‐
cific vascular gene delivery. In this case, the LVs were first coupled to magnetic nanoparti‐
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cles, which were in turn coupled to lipid microbubbles. LVs coupled to magnetic
nanoparticles to target them to specific cell types in vitro using an external magnetic field
has been described before. However, when these LV-nanoparticle constructs are considered
for in vivo use, a sufficient magnetic moment is needed as the particles are subject to flow
velocity within the blood vessels. As the magnetic moment is proportional to particle size,
Mannell et al. coated the LV-nanoparticle constructs with magnetic microbubbles for en‐
largement. Upon intravenous delivery, the LV magnetic microbubbles were first trapped at
the site of interest. Next ultrasound mediated destruction of the microbubbles resulted in
fast release of the LVs at the site of interest with high transduction efficiency without the
cost of higher cytotoxicity (Mannell, Pircher et al. 2012).
In conclusion, there seem to be some general prerequisites for successful transductional tar‐
geting of LVs: (1) use envelope gps with defined receptor binding sites, (2) abolish the natu‐
ral recognition sites of the attachment gp, (3) separate fusion and attachment functions over
two different molecules, (4) avoid the construction of large fusion constructs since their fu‐
sogenic capacities can be severely compromised and (5) avoid the use of immunogenic gps
(Buchholz, Muhlebach et al. 2009).
5. Genomic targeting
Nowadays, LVs have become valuable tools for the treatment of several monogenic disor‐
ders such as hemophilia B, β-thalassemia and X-linked adrenoleukodystrophy (Cartier, Ha‐
cein-Bey-Abina et al. 2012; Payen, Colomb et al. 2012). However, the use of viral vectors that
integrate their cargo into the genome of the host cell can trigger oncogenesis by insertional
mutagenesis. This is exemplified by the incident where two out of 11 patients treated with a
γ-retroviral vector to correct X-linked SCID, developed leukemia. This was caused by the γ-
retroviral construct’s tendency to insert into active genes, in this case the LMO-2 oncogene
(Marshall 2002). Later on, using the same vector type to treat chronic granulomatous dis‐
ease, genomic instability and myelodysplasia was observed (Stein, Ott et al. 2010). These in‐
cidents prompted substantial research into design, safety testing and optimization of
integrating vectors. Thus far several measures have been taken to pose a reduced risk on in‐
sertional mutagenesis such as the development of SIN LVs containing a moderate cellular
promoter (Modlich and Baum 2009; Montini, Cesana et al. 2009). Furthermore LVs are in‐
trinsically less genotoxic than their retroviral counterparts (Montini, Cesana et al. 2006).
Nevertheless, LVs have a higher transduction efficiency, which could counterbalance the re‐
duced risk of mutagenic vector integration into the patient’s genome. In addition, accumu‐
lating studies report the concept of LV-induced clonal dominance related to growth and/or
survival advantage e.g. induced by vector integration and subsequent formation of aberrant‐
ly spliced mRNA forms (Fehse and Roeder 2008; Cavazzana-Calvo, Payen et al. 2010; Cesa‐
na, Sgualdino et al. 2012; Moiani, Paleari et al. 2012). In an extensive analysis to explore the
effect of promoter-enhancer selection on efficacy and safety of LVs, no clear underlying
mechanism could be provided for the observed. They concluded that other ill-defined risk
factors must be involved for oncogenesis, including replicative stress (Ginn, Liao et al. 2010).
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Finally, next to transcriptional activation of neighboring genes, also transcriptional shut off
of the tg has been reported. This was due to chromatin remodeling at the site of insertion
and cessation of the therapeutic effect (Stein, Ott et al. 2010).
Therefore additional strategies have been considered to reduce the side effects related to
random insertion. The most straightforward strategy is to prevent integration of the proviral
cargo by the use of IDLVs. These IDLVs are produced with a mutated integrase, which re‐
sults in prevention of proviral integration and generation of increased levels of circular vec‐
tor episomes within the infected cells. They appear to be safer with only a 0,1 to 2,3% chance
that the episomal transcript gets integrated without a marked loss in effectiveness in terms
of immune stimulatory potential of the IDLV-based vaccines (Vargas, Gusella et al. 2004;
Philippe, Sarkis et al. 2006; Karwacz, Mukherjee et al. 2009; Wanisch and Yanez-Munoz
2009). However, as the lentiviral episomes lack replication signals, they are gradually lost by
dilution in dividing cells and only stable in quiescent cells, which is undesirable for perma‐
nent correction of any genetic disorder. Furthermore also lower tg expression levels have
been reported compared to integrative vectors (Bayer, Kantor et al. 2008). Therefore several
alternative strategies have been brought forward to target the integrative process to a specif‐
ic ‘safe’ genomic site.
In a first attempt, several groups tried to fuse a heterologous DNA binding domain directly
to the integrase. Bushman et al. were the first to evaluate the activity of a hybrid, composed
of the HIV-1 integrase and the lambda repressor. They reported on integration primarily
near the lambda operator sites on the same face of the β-DNA helix (Bushman 1994). Later a
model system was used were the integrase, derived from the avian sarcoma virus or HIV-1
respectively was fused to the Escherichia coli LexA repressor protein DNA binding domain
(Katz, Merkel et al. 1996; Holmes-Son and Chow 2000). When this construct was packaged
into the virion in trans either by replacing the original integrase gene or by cloning it adja‐
cent to the HIV-1 accessory protein Vpr, they observed that this enhanced the use of integra‐
tion sites adjacent to the lexA operators. In another study, the HIV-1 derived integrase was
fused to a synthetic polydactyl zinc finger protein E2C, which binds specifically to a contig‐
uous 18 bp E2C recognition site (Tan, Dong et al. 2006). Although in all studies clearly a
higher preference for integration near the target sequence of choice was observed, this also
implicated reduced DNA-binding specificity of the fusion protein with associated decrease
of integration frequency of about 80 percent compared to viruses containing wild type inte‐
grase. Furthermore this strategy is also limited by the difficulty to incorporate the fusion
protein into infectious virions (Michel, Yu et al. 2010).
Another strategy is targeting the integration away from genes using tethering domains
linked to the host cell-encoded transcriptional co-activator lens epithelium-derived growth
factor/p75 (LEDGF/p75), a cellular integrase binding protein. For example the LEDGF/p75
chromatin interaction-binding domain has been replaced with CBX1, which binds histone
H3 di- or trimethylated on K9. Subsequently proviral integration was directed to pericentric
heterochromatin and intergenic regions (Llano, Vanegas et al. 2006; Ferris, Wu et al. 2010;
Gijsbers, Ronen et al. 2010; Silvers, Smith et al. 2010). As this requires engineering of a host
cell protein, it is not feasible for clinical applications at the present stage (Izmiryan, Basma‐
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ciogullari et al. 2011). Site-specific proviral integration can also be mediated by the use of
site-specific recombinases. The best known are derived from the lambda integrase family of
enzymes and include the bacteriophage P1 Cre recombinase, bacteriophage lambda inte‐
grase, the yeast Flp recombinase and bacterial XerCD recombinase. They catalyze site specif‐
ic recombination by a transient DNA-protein covalent linkage that brings two specific DNA
repeats together (Van Duyne 2001). Depending on the orientation of the DNA repeats, the
DNA segment will either be excised or inverted when in the same or opposite orientation
respectively (Figure 5A, adapted from http://www.ruf.rice.edu/~rur/issue1_files/
norman.html). The Cre-loxP system has been developed for gene studies to conditionally
knock out a target gene in a cell- or tissue specific manner to overcome embryonic lethality
due to permanent inactivation of the target gene in an early developmental stage (Ray, Fa‐
gan et al. 2000). This system is based on two palindromic loxP sites of 34 bp that flank the
gene of interest. Although these loxP sites are prevalent in the genomes of bacteriophages,
they are absent in the mouse genome where they have to be introduced by targeted muta‐
genesis (Kos 2004). Throughout the human genome, however, loxP-like sequences or pseu‐
do-loxP sites are present that can be recognized by either wild-type Cre or Cre variants. This
last feature enables site-specific insertion of a gene in a defined loxP site in the human ge‐
nome if a Cre recombinase is provided in cis or trans. Michel et al. evaluated the feasibility of
combining the Cre-loxP system for gene targeting with the versatile gene delivery system of
LVs for site-specific gene insertion in human cell lines. They transduced a loxP site contain‐
ing cell line with a LV containing Cre recombinase in trans as a fusion protein to the HIV
accessory protein Vpr. Moreover the LV contained a cassette containing a loxP site followed
by the neomycin resistant gene, inserted in the U3 region of the 3’LTR. Upon reverse tran‐
scription, the loxP-neo sequence would appear in both LTRs, thereby providing a substrate
for recombination that could be catalyzed by the virion-associated Vpr-Cre. Upon this re‐
combination step, a circular product was produced that was on his turn inserted into the
loxP site of the cell line, again catalyzed by virion-associated Vpr-Cre. Another example is
provided by the group of Jiang et al. who demonstrated a selective inhibitory effect on the
lens epithelial cells and not the retinal pigment epithelial cells (Jiang, Lu et al. 2011). There‐
fore they used an enhanced Cre/loxP system with a LV expressing Cre under the control of
the lens-specific promoter LEP503 in combination with another LV that contained a stiffer
sequence encoding eGFP with a functional polyadenylation signal between two loxP sites,
followed by the HSV-TK gene, both under the control of the human phosphoglycerate kin‐
ase promoter. Expression of the downstream HSV-TK was activated by co-expression of Cre
under the control of the lens-specific promoter LEP503. Although this technology allows
site-specific tg insertion, there are only a limited amount of pseudo-loxP sites in the human
genome and even none in the mouse genome, which makes this technique unusable for fun‐
damental research in laboratory animals. Furthermore, two recombination events are re‐
quired which has a major impact on its efficiency.
A recent strategy makes use of site-specific endonucleases to target the tg to neutral ‘safe
harbor’ genome regions or stimulate the process of homologous recombination for gene re‐
pair (Fischer, Hacein-Bey-Abina et al. 2011). Endonucleases induce site-specific ds breaks
that can be repaired by homology-directed repair, a form of homologous recombination that
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uses a copy of the genetic information from the broken DNA molecule. When the latter is
provided by the same or another LV, this copy will be used to repair the ds break (Urnov,
Miller et al. 2005; O'Driscoll and Jeggo 2006). The advantage of gene repair/correction is that
both function and expression of the affected gene are restored while the risk associated with
random vector integration is avoided. Besides the advantage of the reduced risk for inser‐
tional mutagenesis, this strategy is also used to target genes in order to knock them down or
replace them with another gene by homologous recombination. The disadvantage is that the
nuclease coding sequences are expressed for several days, which is not optimal for transla‐
tion to the clinic due to the background off-target generation of dsDNA breaks.
One possibility is the use of the zinc finger nuclease strategy. For this, the Cys2His2 class of
zinc finger DNA binding domains is engineered to recognize a DNA sequence of interest,
fused to the nuclease domain of the FokI type II restriction endonuclease to yield a highly
specific zinc finger (Figure 5 B, adapted from http://biol1020-2011-2.blogspot.be/2011/09/
zinc-finger-nucleases-zfn-emerging.html) (Kim, Cha et al. 1996; Pabo, Peisach et al. 2001).
When two different zinc fingers are designed to bind the same sequence of interest in the
opposite orientation, this will allow dimerization of the FokI domains which leads to a zinc
finger induced dsDNA break (Bitinaite, Wah et al. 1998). Various strategies have been devel‐
oped to engineer the Cys2His2 zinc fingers in order to bind a specific sequence either by
modular assembly or by selection strategies using phage display or a cellular selection sys‐
tem. Naldini et al. evaluated the use of zinc finger nucleases in combination with an IDLV
for gene editing. Therefore they co-transduced several cell lines with three different IDLVs,
one encoding the donor sequence and two encoding the two zinc fingers (Lombardo, Geno‐
vese et al. 2007). A few years later they also used this strategy to assess zinc finger specificity
genome-wide by comprehensively mapping the locations of the IDLV integration sites in
cells co-transduced with GFP and zinc finger encoding LVs (Gabriel, Lombardo et al. 2011).
They observed a very high efficiency and specificity, yet a measurable rate of vector integra‐
tion at unidentified sites occurred with this approach, which is the sum of zinc finger medi‐
ated and background levels of IDLV integration. Moreover co-transduction with three
different LVs may be a rate-limiting step in this system. Therefore the use of a single con‐
struct to express the zinc fingers and deliver the donor tg must be evaluated, especially for
less permissive cells such as hematopoietic progenitors.
Another way to target the proviral genome is by the provision of a vector-associated mega‐
nuclease encoded by a separate vector or supplied as a protein within the viral particle.
(Izmiryan, Basmaciogullari et al. 2011). For the latter, Ismiryan et al. fused the prototypic
meganuclease I-SceI from yeast to Vpr. This avoided the potentially toxic sustained expres‐
sion of the introduced endonuclease. IDLVs encoding the donor sequence and containing
the meganuclease-SceI fusion construct were tested in reporter cells in which targeting
events were scored by the repair of a puromycin resistance gene. They reported a two-fold
higher frequency of the expected recombination event when the nuclease was delivered as a
protein rather than encoded by a separate vector and therefore improved both the safety
and efficacy of this LV-based gene targeting system. In conclusion, although the field of ge‐
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nomic targeting is relatively new for LV-based gene therapy, it opens a tremendous amount
of new possibilities.
Figure 5. Schematic representation of targeted genome modification by the Cre-loxP system (A) or by the zinc-finger
nuclease complex (B). Cre recombinases recognize specific loxP sites in the genome, bind them en bring them togeth‐
er. Depending on their orientation this leads to excision (same orientation) or inversion (opposite orientation) of the
sequence flanked by the two loxP sites(A). Two individual zinc finger molecules each recognize a 9 to 18 bp DNA se‐
quence using between three and six individual zinc finger repeats that bind the major groove of DNA. The DNA se‐
quences are non-palindromic DNA sites located respectively up -and downstream of the intended cleavage site, which
is mostly about 5-7 bp long. If the zinc finger domains are perfectly specific for their intended target site then even a
pair of three-finger ZFNs that recognize a total of 18 bp can theoretically target a single locus in a mammalian ge‐
nome. Next, the associated Fok1 nucleases dimerize and induce a double stranded break which can be restored by
either non-homologous end-joining or homology-directed repair, which faithfully restores the original sequence by
copying it from the sister chromatid or using the homologous sequence provided by a LV(B).
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6. Concluding remarks
LVs have proven to be efficient vehicles to deliver one or more tgs to any cell type of choice,
which has led to a promising list of therapeutic applications. As the demand for experimen‐
tation in gene delivery to specific cell types increases, technologies that precisely target LV-
based gene expression will become more important for research and clinical applications.
Four main groups of strategies with their own possibilities as well as difficulties have been
developed so far. Self-evidently, further optimization and fine-tuning of these strategies is a
necessity to fulfill the expectations for targeted LV delivery in vivo. In addition to extra opti‐
mization steps, combinations of two or more of these strategies can also lead to an overall
more selective, efficient and most importantly, safe LV system. Several attempts to combine
the different strategies have been reported (Brown, Cantore et al. 2007; Pariente, Morizono
et al. 2007; Escors and Breckpot 2011). Pariente et al. for example, reported on a LV that was
transductionally targeted to prostate cancer bone metastases by a modified sindbis virus en‐
velope that interacts with PSCA and transcriptionally targeted with a prostate cell specific
promoter. This dual-targeted LV enhanced specificity to prostate cancer bone metastases af‐
ter systemic delivery with respect to individual transcriptional or transductional targeting.
As the developed targeting strategies already resulted in a major step forward for LV-based
gene therapy, their potential will most likely be more exploited in the future, paving the
way towards an all-embracing LV-based tg vehicle for the gene therapeutic field.
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